The Future of Molecular-Targeted Cancer Chemoprevention

Gastroenterology

Volumn 135, Issue 6, 2008, Pages 1834-1841

  Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; CELECOXIB; EFLORNITHINE; ERLOTINIB; FINASTERIDE; HEPATITIS B VACCINE; PLACEBO; RALOXIFENE; ROFECOXIB; SULINDAC; TAMOXIFEN; WART VIRUS VACCINE;

ARTICLE; BIOLOGY; BREAST CANCER; BREAST CARCINOMA; CANCER MODEL; CANCER RISK; CARDIOVASCULAR DISEASE; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ESOPHAGEAL ADENOCARCINOMA; GERM LINE; HEPATITIS B; HUMAN; INTRADUCTAL CARCINOMA; KIDNEY CANCER; LEUKOPLAKIA; LIVER CANCER; LIVER CELL CARCINOMA; MOUTH CANCER; NEOPLASM; NONHUMAN; OROPHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK BENEFIT ANALYSIS; STOMACH CANCER; THROMBOEMBOLISM; THROMBOSIS; UTERINE CERVIX CANCER; UTERUS CANCER; VAGINA CANCER; VULVA CANCER;

EID: 57249094017     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.10.073     Document Type: Article

References (86)

1. Lippman S.M., Benner S.E., and Hong W.K. Cancer chemoprevention. J Clin Oncol 12 (1994) 851-873
2. Hong W.K., and Sporn M.B. Recent advances in chemoprevention of cancer. Science 278 (1997) 1073-1077
3. Kelloff G.J., Lippman S.M., Dannenberg A.J., et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res 12 (2006) 3661-3697
4. Eberhart C.E., Coffey R.J., Radhika A., et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
5. Buchanan F.G., and DuBois R.N. Connecting COX-2 and Wnt in cancer. Cancer Cell 9 (2006) 6-8
6. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
7. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 (2006) 873-884
8. Hallak A., Alon-Baron L., Shamir R., et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 48 (2003) 1998-2002
9. Baron J.A., Sandler R.S., Bresalier R.S., et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131 (2006) 1674-1682
10. Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol 24 (2006) 5593-5600
11. +-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res 1 (2008) 241-249
12. Nemenoff R., Meyer A.M., Hudish T.M., et al. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisome proliferator-activated receptor γ. Cancer Prev Res 1 (2008) 349-356
13. Holla V.R., Backlund M.G., Yang P., et al. Regulation of Prostaglandin Transporters in Colorectal Neoplasia. Cancer Prev Res 1 (2008) 93-99
14. Shureiqi I., Jiang W., Zuo X., et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A 100 (2003) 9968-9973
15. Shureiqi I., Wu Y., Chen D., et al. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res 65 (2005) 11486-11492
16. Herbst R.S., Heymach J.V., and Lippman S.M. Lung cancer. N Engl J Med 359 (2008) 1367-1380
17. Majumder P.K., Febbo P.G., Bikoff R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 (2004) 594-601
18. Yang Y., Iwanaga K., Raso M.G., et al. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS ONE 3 (2008) e2220
19. Wislez M., Spencer M.L., Izzo J.G., et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 65 (2005) 3226-3235
20. Yoo C.B., Chuang J.C., Byun H.-M., et al. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (2008) 1940-6207
21. Meyskens Jr. F.L., McLaren C.E., Pelot D., et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 1 (2008) 32-38
22. Torrance C.J., Jackson P.E., Montgomery E., et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6 (2000) 1024-1028
23. Lippman S.M., and Lee J.J. Reducing the "risk" of chemoprevention: defining and targeting high risk-2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res 66 (2006) 2893-2903
24. Abbruzzese J.L., and Lippman S.M. The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell 6 (2004) 321-326
25. Szabo E. Proliferative changes in chemoprevention trials: learning from secondary endpoints. J Natl Cancer Inst 99 (2007) 1565-1567
26. Gail M.H., Brinton L.A., Byar D.P., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81 (1989) 1879-1886
27. Spitz M.R., Hong W.K., Amos C.I., et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 99 (2007) 715-726
28. Fears T.R., Guerry D., Pfeiffer R.M., et al. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 24 (2006) 3590-3596
29. Galipeau P.C., Li X., Blount P.L., et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4 (2007) e67
30. Lee J.J., Hong W.K., Hittelman W.N., et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 6 (2000) 1702-1710
31. Rosin M.P., Cheng X., Poh C., et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 6 (2000) 357-362
32. Papadimitrakopoulou VA, Lee JJ, William WN, et al. Randomized trial of 13-cis retinoic acid versus retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. In press.
33. Vokes E.E., Weichselbaum R.R., Lippman S.M., et al. Head and neck cancer. N Engl J Med 328 (1993) 184-194
34. Lippman S.M., Batsakis J.G., Toth B.B., et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328 (1993) 15-20
35. Rosin M.P., Lam W.L., Poh C., et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res 62 (2002) 6447-6450
36. Gauthier M.L., Berman H.K., Miller C., et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 12 (2007) 479-491
37. Belinsky S.A., Liechty K.C., Gentry F.D., et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66 (2006) 3338-3344
38. Amos C.I., Wu X., Broderick P., et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40 (2008) 616-622
39. Amundadottir L.T., Sulem P., Gudmundsson J., et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 38 (2006) 652-658
40. Beane J., Sebastiani P., Whitfield T.H., et al. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res 1 (2008) 56-64
41. Spitz M.R., Etzel C.J., Dong Q., et al. An expanded risk prediction model of lung cancer. Cancer Prev Res 1 (2008) 250-254
42. Izzo J.G., Papadimitrakopoulou V.A., Liu D.D., et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 95 (2003) 198-205
43. Herbst R.S., and Lippman S.M. Molecular signatures of lung cancer-toward personalized therapy. N Engl J Med 356 (2007) 76-78
44. Lippman S.M., and Heymach J.V. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 13 (2007) 4035-4041
45. Siveke J.T., Einwachter H., Sipos B., et al. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 12 (2007) 266-279
46. Lipkin S.M., Rhee J., Zell J., et al. Molecular cancer prevention: phase IIa trial of erlotinib for IPMNs and the prevention of pancreatic cancer. AACR Meeting Abstracts 2006 (2006) CS04-03
47. Giardiello F.M., Hamilton S.R., Krush A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328 (1993) 1313-1316
48. Sandler R.S., Halabi S., Baron J.A., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348 (2003) 883-890
49. Baron J.A., Cole B.F., Sandler R.S., et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348 (2003) 891-899
50. Benamouzig R., Deyra J., Martin A., et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125 (2003) 328-336
51. Logan R.F., Grainge M.J., Shepherd V.C., et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134 (2008) 29-38
52. Flossmann E., and Rothwell P.M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369 (2007) 1603-1613
53. Chan A.T., Giovannucci E.L., Meyerhardt J.A., et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134 (2008) 21-28
54. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
55. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
56. Arber N., Eagle C.J., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885-895
57. Bertagnolli MM, Zauber AG, Hawk ET. The Adenoma Prevention with Celecoxib (APC) trial: five-year efficacy and safety results. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research 2008:abstr. LB-141.
58. Solomon S.D., Wittes J., Finn P.V., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117 (2008) 2104-2113
59. Sporn M.B., and Hong W.K. Clinical prevention of recurrence of colorectal adenomas by the combination of difluoromethylornithine and sulindac: an important milestone. Cancer Prev Res 1 (2008) 9-11
60. Cho N.L., Redston M., Zauber A.G., et al. Aberrant crypt foci in the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res 1 (2008) 21-31
61. Lance P., and Hamilton S.R. Sporadic Aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention. Cancer Prev Res 1 (2008) 4-8
62. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
63. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
64. Lippman S.M., and Brown P.H. Tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst 91 (1999) 1809-1819
65. Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 (2002) 817-824
66. Cuzick J., Forbes J.F., Sestak I., et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99 (2007) 272-282
67. Fisher B., Dignam J., Wolmark N., et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353 (1999) 1993-2000
68. Gronwald J., Tung N., Foulkes W.D., et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118 (2006) 2281-2284
69. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (2006) 2727-2741
70. Strecker T, Zhang Y, Hill J, et al. The dual tyrosine kinase inhibitor, lapatinib, prevents estrogen receptor-negative breast cancer in mice by suppressing the development of pre-malignant lesions. J Natl Cancer Inst. In press.
71. Brown P.H., Subbaramaiah K., Salmon A.P., et al. Combination chemoprevention of her2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid x receptor-selective retinoid. Cancer Prev Res 1 (2008) 208-214
72. Moinpour C.M., Darke A.K., Donaldson G.W., et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 (2007) 1025-1035
73. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
74. Thompson I.M., Chi C., Ankerst D.P., et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98 (2006) 1128-1133
75. Redman M.W., Tangen C.M., Goodman P.J., et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res 1 (2008) 174-181
76. Lucia M.S., Epstein J.I., Goodman P.J., et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 (2007) 1375-1383
77. Lucia M.S., Darke A.K., Goodman P.J., et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res 1 (2008) 167-173
78. Logothetis C.J., and Schellhammer P.F. High-grade prostate cancer and the Prostate Cancer Prevention Trial. Cancer Prev Res 1 (2008) 151-152
79. Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336 (1997) 1855-1859
80. D'Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356 (2007) 1944-1956
81. Finn O.J. Cancer immunology. N Engl J Med 358 (2008) 2704-2715
82. Fukase K., Kato M., Kikuchi S., et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372 (2008) 392-397
83. Blaser M.J. Understanding microbe-induced cancers. Cancer Prev Res 1 (2008) 15-20
84. Islami F., and Kamingar F. Helicobacter pylori and esophageal cancer risk-a meta-analysis. Cancer Prev Res 1 (2008) 329-338
85. Martinez M.E., O'Brien T.G., Fultz K.E., et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A 100 (2003) 7859-7864
86. Lippman S.M., Goodman P.J., Klein E.A., et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97 (2005) 94-102